REVIEW

Oxidative Stress and Hematopoietic Stem Cell Dysfunction in Sickle Cell Anemia,E Oobeagu

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

emmanuelobeagu@yahoo.com, +2348037369912

ABSTRACT

Sickle Cell Anemia (SCA) is a genetic blood disorder characterized by the production of abnormal hemoglobin S, leading to red blood cell sickling and a range of severe health complications. Recent research highlights the significant role of oxidative stress in the pathophysiology of SCA, particularly its impact on hematopoietic stem cells (HSCs). Oxidative stress in SCA originates from both intrinsic factors, such as the sickling process, and extrinsic sources, including chronic inflammation and hypoxia. This review explores how reactive oxygen species (ROS) generated by these factors contribute to HSC dysfunction, impairing hematopoiesis and exacerbating disease progression. The review delves into the mechanisms by which oxidative stress affects HSCs, focusing on the generation of ROS and their effects on HSC viability, differentiation, and self-renewal. We examine how oxidative damage to DNA, lipids, and proteins disrupts HSC function and contributes to the progression of SCA. Additionally, the review highlights the impact of phospholipid oxidation on HSCs, discussing how oxidative damage leads to alterations in HSC function and contributes to disease severity. Emerging therapeutic strategies aimed at reducing oxidative stress offer hope for improving SCA management.

Keywords: Sickle Cell Anemia, Oxidative Stress, Hematopoietic Stem Cells, Reactive Oxygen Species, Therapeutic Interventions

Introduction

Sickle Cell Anemia (SCA) is a severe, inherited blood disorder caused by a single nucleotide mutation in the hemoglobin beta chain gene, leading to the production of abnormal hemoglobin S (HbS).1-2 This genetic defect results in the deformation of red blood cells into a sickle shape under low-oxygen conditions, causing a range of clinical manifestations including pain crises, hemolysis, and organ damage. Despite significant advancements in the understanding and management of SCA, there remains a critical need for new therapeutic strategies to address the disease's complex pathophysiology. Recent research has increasingly focused on the role of oxidative stress in SCA, particularly its impact on hematopoietic stem cells (HSCs), which are fundamental for maintaining hematopoiesis and overall blood health.3-6 SCA research has historically concentrated on the mechanisms of red blood cell sickling and the resulting vaso-occlusive crises.7 Early studies identified that HbS polymerizes under deoxygenated conditions,

causing red blood cells to assume a rigid, sickle shape that can obstruct blood flow in capillaries and lead to painful episodes and chronic organ damage.8-9 While these studies provided a foundational understanding of the disease, they primarily focused on the symptoms rather than the cellular and molecular processes underpinning them. Over the past few decades, researchers have recognized that oxidative stress plays a pivotal role in SCA. Oxidative stress refers to an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize these molecules. In SCA, oxidative stress is not merely a consequence of sickling but also a driver of disease pathogenesis. ROS contribute to the chronic inflammation, endothelial dysfunction, and hemolysis observed in SCA. This expanded view of oxidative stress has opened new avenues for research into how ROS affect not only red blood cells but also the broader hematopoietic system.10-13

Hematopoietic stem cells (HSCs) are multipotent cells responsible for the generation of all blood cell lineages throughout an individual's lifetime. Recent studies have highlighted that oxidative stress adversely affects HSCs, compromising their ability to self-renew and differentiate into mature blood cells. In the context of SCA, oxidative stress disrupts HSC function, which can exacerbate anemia and influence disease progression.14-15 In SCA, oxidative stress arises from multiple sources including the sickling of red blood cells, chronic inflammation, and hypoxic conditions. The sickling process itself generates ROS through various mechanisms, including the release of free hemoglobin and the subsequent formation of hydrogen peroxide and other reactive molecules. Additionally, chronic inflammation and hypoxia in SCA patients further exacerbate oxidative stress, creating a vicious cycle that affects both red blood cells and HSCs.16-17 Oxidative stress inflicts damage on cellular components such as DNA, lipids, and proteins. In HSCs, oxidative DNA damage can lead to mutations and affect stem cell function, while lipid peroxidation compromises cell membrane integrity. The cumulative effects of oxidative damage on HSCs can impair their ability to generate healthy blood cells, contributing to the anemia and other complications seen in SCA.17-20 The HSC microenvironment, or niche, plays a critical role in regulating HSC function. Oxidative stress alters the HSC niche, disrupting the balance between HSC self-renewal and differentiation. The oxidative environment can affect both the niche cells and the HSCs themselves, leading to a decline in hematopoietic function and contributing to disease severity.

Oxidative Stress in Sickle Cell Anemia

Oxidative stress is a crucial factor in the pathophysiology of Sickle Cell Anemia (SCA), significantly contributing to the disease's progression and severity. In SCA, oxidative stress arises from various sources and exerts detrimental effects on red blood cells, endothelial cells, and hematopoietic stem cells (HSCs).21 The sickling of red blood cells is a hallmark of SCA, driven by the polymerization of hemoglobin S (HbS) under low-oxygen conditions. This polymerization is not only responsible for the sickle shape of the red blood cells but also generates oxidative stress. During sickling, hemoglobin S aggregates to form long, rigid fibers that deform the red blood cells, creating a hypoxic environment that enhances oxidative reactions. These reactions produce reactive oxygen species (ROS) such as superoxide anions and hydrogen peroxide, which contribute to oxidative damage in red blood cells and other tissues.22-25 Hemolysis, the breakdown of red blood cells, is a

common feature of SCA and a significant source of oxidative stress.26 The lysis of sickled red blood cells releases free hemoglobin into the bloodstream. Free hemoglobin can degrade into methemoglobin, which reacts with oxygen to produce hydrogen peroxide and other ROS. This process exacerbates oxidative stress and further damages cellular components, including lipids, proteins, and DNA. SCA is characterized by chronic inflammation, which contributes to oxidative stress.27 Inflammatory cells such as neutrophils and macrophages release ROS as part of the inflammatory response. This chronic inflammatory state exacerbates oxidative damage to red blood cells and other tissues. Pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), promote the production of ROS and further contribute to oxidative stress.

Oxidative stress in SCA leads to the damage of cellular lipids, proteins, and DNA. Lipid peroxidation, a process where ROS attack lipids in cell membranes, results in the formation of lipid peroxides and aldehydes, which disrupt membrane integrity and function. Protein oxidation affects enzymatic activity and structural integrity, impairing cellular functions. DNA damage from ROS can lead to mutations and genomic instability, further complicating disease pathology.28-29 The integrity of the red blood cell membrane is crucial for maintaining cell shape and function. Oxidative stress causes the oxidation of membrane lipids and proteins, leading to increased membrane permeability and the premature destruction of red blood cells. This membrane damage contributes to the hemolysis observed in SCA and exacerbates the disease's symptoms. Nitric oxide (NO) is a vasodilator that plays a protective role in the vascular system. In SCA, oxidative stress leads to the scavenging of NO by ROS, reducing its availability and impairing vasodilation.30 This disruption of NO homeostasis contributes to vaso-occlusive crises and exacerbates the vascular complications associated with SCA. Oxidative stress significantly affects HSCs, leading to impaired hematopoiesis and exacerbation of SCA.31 ROS can damage HSCs directly, leading to alterations in cell survival, proliferation, and differentiation. This oxidative damage impacts the ability of HSCs to maintain normal blood cell production and contributes to the chronic anemia observed in SCA. Oxidative stress induces DNA damage in HSCs, which can lead to mutations and genomic instability. This damage accelerates HSC aging and reduces the regenerative capacity of the hematopoietic system. The accumulation of DNA damage in HSCs contributes to the decline in hematopoietic function seen in SCA patients.

Phospholipid Oxidation and HSC Dysfunction

Phospholipid oxidation is a critical aspect of oxidative stress in Sickle Cell Anemia (SCA), affecting both red blood cells and hematopoietic stem cells (HSCs).32 Phospholipid oxidation in SCA is primarily driven by reactive oxygen species (ROS) generated during sickling and hemolysis. The oxidative stress environment leads to the peroxidation of membrane lipids, a process where ROS attack the polyunsaturated fatty acids in phospholipids, resulting in the formation of lipid peroxides. These lipid peroxides are highly reactive and can further damage cellular components, including proteins and DNA. Phospholipid peroxidation disrupts the structural integrity of cell membranes. In red blood cells, this damage leads to membrane rigidity, altered cell shape, and increased susceptibility to hemolysis. Similarly, oxidative damage to phospholipids affects HSCs, leading to

membrane instability and impaired cellular functions. The accumulation of oxidized phospholipids can trigger inflammatory responses and further exacerbate oxidative stress. Oxidative stress-induced phospholipid peroxidation directly affects HSC viability.33 Damaged phospholipids disrupt the HSC membrane, leading to loss of cellular integrity and apoptosis. The accumulation of oxidized phospholipids can also interfere with HSC proliferation and differentiation, essential processes for maintaining normal hematopoiesis. Phospholipid oxidation impairs HSC differentiation by altering the signaling pathways involved in hematopoiesis. Oxidative stress affects transcription factors and cellular signaling cascades that regulate HSC differentiation into various blood cell lineages. Disruption of these pathways can lead to an imbalance in hematopoiesis, contributing to anemia and other hematological disorders observed in SCA.

The HSC microenvironment, or niche, plays a vital role in regulating HSC function.34 Oxidative stress and phospholipid peroxidation affect the HSC niche by altering the interactions between HSCs and niche cells. This disruption can lead to changes in the HSC microenvironment that adversely impact HSC self-renewal and differentiation processes. Phospholipid oxidation plays a role in the pathogenesis of vaso-occlusive crises in SCA.35 Oxidative stress leads to the modification of cell membranes and the release of pro-inflammatory mediators. These changes contribute to endothelial dysfunction, increased blood viscosity, and the formation of blood clots, which are central to the development of vaso-occlusive crises. Phospholipid oxidation interacts with other pathophysiological factors in SCA, such as nitric oxide (NO) scavenging and hemolysis.36 The oxidative modification of phospholipids exacerbates these factors, creating a feedback loop that worsens vaso-occlusive crises and contributes to the overall severity of SCA. Given the significant role of phospholipid oxidation in SCA, antioxidant therapies represent a promising approach for mitigating oxidative damage.37 Antioxidants such as vitamin E and SOD mimetics are being investigated for their potential to reduce phospholipid peroxidation and alleviate SCA symptoms. These therapies aim to restore the balance between ROS production and antioxidant defenses, thereby protecting HSCs and improving disease outcomes. Research is ongoing to develop novel pharmacological agents that specifically target oxidative stress and phospholipid oxidation in SCA. These agents include inhibitors of lipid peroxidation and modulators of oxidative stress pathways. By targeting the mechanisms of phospholipid oxidation, these drugs aim to protect HSCs and improve hematopoietic function. Combination therapies that integrate antioxidants with other treatment modalities offer a strategic approach for managing oxidative stress in SCA. By combining antioxidants with traditional SCA treatments such as hydroxyurea or blood transfusions, these therapies aim to provide a multifaceted approach to disease management.

Impact of Oxidative Stress on Hematopoietic Stem Cells

Oxidative stress plays a pivotal role in the pathogenesis of Sickle Cell Anemia (SCA), significantly impacting hematopoietic stem cells (HSCs).38 Oxidative stress in SCA generates reactive oxygen species (ROS) that cause direct damage to HSC components. ROS, including superoxide anions, hydrogen peroxide, and hydroxyl radicals, are byproducts of metabolic processes and pathological events in SCA. These ROS species induce oxidative damage to critical cellular macromolecules such as lipids, proteins, and DNA, leading to compromised HSC function.

Lipid peroxidation is a key outcome of oxidative stress, where ROS attack polyunsaturated fatty acids in cell membranes. This process generates lipid peroxides, which disrupt membrane integrity and fluidity. In HSCs, lipid peroxidation can impair cell membrane stability, affect cell signaling, and lead to apoptosis. Oxidative stress leads to the oxidation of cellular proteins, affecting their structure and function. Oxidized proteins may lose enzymatic activity, alter cellular signaling pathways, and contribute to cellular dysfunction. In HSCs, protein oxidation impairs essential functions such as DNA repair and cell cycle regulation. ROS-induced DNA damage in HSCs includes the formation of 8-oxoguanine, single-strand breaks, and cross-linking. This genetic damage can lead to mutations, genomic instability, and compromised stem cell function. Persistent DNA damage contributes to the aging of HSCs and affects their regenerative capacity.

Oxidative stress affects HSC viability and proliferation through various mechanisms, including apoptosis and cell cycle arrest. Elevated ROS levels in SCA lead to oxidative damage that triggers cell death pathways and impairs the proliferation of HSCs.39 Increased ROS levels can induce apoptosis in HSCs through the activation of pro-apoptotic signaling pathways. ROS-mediated activation of caspases and mitochondrial dysfunction are key mechanisms by which oxidative stress leads to HSC apoptosis. Oxidative stress-induced DNA damage can lead to cell cycle arrest in HSCs. By activating checkpoints in the cell cycle, HSCs may enter a quiescent state or undergo senescence, reducing their ability to proliferate and contribute to hematopoiesis. Oxidative stress affects HSC differentiation and hematopoiesis by altering key signaling pathways and transcription factors involved in these processes. Oxidative stress can disrupt HSC differentiation by modifying signaling pathways and transcription factors that regulate hematopoiesis. For example, oxidative stress can inhibit the expression of critical transcription factors such as GATA-1 and PU.1, leading to impaired differentiation into various blood cell lineages.

Oxidative stress can cause an imbalance in hematopoiesis by favoring the expansion of certain cell types over others. For instance, oxidative stress may promote the development of myeloid over erythroid cells, contributing to the anemia and other hematological abnormalities seen in SCA.40 The HSC niche is a specialized microenvironment that regulates HSC function. Oxidative stress can alter the HSC niche by affecting interactions between HSCs and niche cells, thereby influencing HSC maintenance and function. Oxidative stress can affect the interactions between HSCs and their niche, which is composed of stromal cells, extracellular matrix components, and signaling molecules. Changes in the HSC niche can disrupt the balance between HSC self-renewal and differentiation. Oxidative stress can impair the functions of niche cells, such as osteoblasts and endothelial cells, which provide essential support for HSCs. This impairment affects the niche's ability to support HSC maintenance and function. Antioxidant therapies aim to neutralize ROS and reduce oxidative damage in HSCs. Agents such as vitamin E, N-acetylcysteine, and superoxide dismutase mimetics are being investigated for their potential to protect HSCs from oxidative stress. Novel pharmacological agents that specifically target oxidative stress pathways are being developed. These agents aim to reduce ROS production, enhance antioxidant defenses, and protect HSCs from oxidative damage. Combination therapies that integrate antioxidants with other treatment modalities offer a comprehensive approach to managing oxidative stress in SCA. These therapies aim to provide multifaceted protection for HSCs and improve disease outcomes.41-45

Addressing oxidative stress in Sickle Cell Anemia (SCA) represents a promising avenue for therapeutic intervention.46 The multifaceted nature of oxidative stress in SCA, involving reactive oxygen species (ROS) production, lipid peroxidation, and cellular damage, necessitates a range of therapeutic strategies aimed at mitigating oxidative damage and improving patient outcomes. Vitamin E is a well-known antioxidant that neutralizes ROS and prevents lipid peroxidation. Clinical studies have demonstrated that vitamin E supplementation can reduce oxidative stress in SCA patients, improve red blood cell membrane stability, and potentially reduce the frequency of vaso-occlusive crises. N-Acetylcysteine (NAC) serves as a precursor for glutathione, a major intracellular antioxidant. NAC has been shown to reduce oxidative stress and improve endothelial function in SCA. By increasing cellular glutathione levels, NAC mitigates ROS-induced damage and supports antioxidant defenses. L-Arginine, a precursor of nitric oxide (NO), has been explored for its antioxidant properties. NO, produced from L-Arginine, acts as a vasodilator and can alleviate oxidative stress by scavenging ROS. L-Arginine supplementation has been shown to improve blood flow and reduce oxidative damage in SCA.47 Hydroxyurea, a well-established therapy for SCA, exerts its effects through multiple mechanisms, including the induction of fetal hemoglobin (HbF) and reduction of oxidative stress. Hydroxyurea enhances nitric oxide production, which helps to counteract oxidative stress and improve red blood cell deformability. Curcumin, a polyphenol derived from turmeric, possesses potent antioxidant and anti-inflammatory properties. Curcumin has been shown to reduce oxidative stress in SCA by decreasing ROS levels and modulating inflammatory pathways. Statins, primarily used for cholesterol management, also have antioxidant effects. They reduce oxidative stress by inhibiting the mevalonate pathway, which decreases ROS production. Clinical trials have explored the use of statins in SCA to improve endothelial function and reduce oxidative damage.

Gene therapy aims to correct the genetic defect responsible for SCA.48 Emerging approaches include the use of gene editing techniques, such as CRISPR/Cas9, to modify the β-globin gene and increase HbF levels, which indirectly reduces oxidative stress associated with sickling. Research is ongoing into the development of antioxidant enzyme mimetics, such as superoxide dismutase (SOD) mimetics and catalase mimetics. These agents aim to replicate the activity of endogenous antioxidants and provide targeted protection against ROS-induced damage. Pharmacological agents that enhance NO production or mimic its effects represent a novel therapeutic approach. Drugs like nitrite or nitrates aim to increase NO bioavailability, reduce oxidative stress, and improve vascular health in SCA patients.49 Combination therapies that pair antioxidants with traditional SCA treatments, such as hydroxyurea or blood transfusions, offer a comprehensive approach to managing oxidative stress. These regimens aim to maximize therapeutic benefits by targeting multiple aspects of disease pathophysiology. Multimodal therapeutic strategies that combine antioxidants, gene therapy, and pharmacological agents represent a promising future direction for SCA treatment. These approaches aim to address both the genetic and oxidative stress aspects of the disease.

Conclusion

Sickle Cell Anemia (SCA) is a complex genetic disorder characterized by chronic hemolysis, vaso-occlusive crises, and a range of systemic complications. Central to the pathophysiology of SCA is oxidative stress, which drives much of the disease's clinical manifestations and contributes to hematopoietic stem cell (HSC) dysfunction. Oxidative stress in SCA arises from the chronic

breakdown of sickle hemoglobin, leading to increased production of reactive oxygen species (ROS). These ROS contribute to a cascade of cellular damage, including lipid peroxidation, protein oxidation, and DNA damage. The persistent oxidative damage not only exacerbates anemia and vaso-occlusive crises but also plays a critical role in the dysfunction of HSCs. ROS-induced damage impairs HSC viability, proliferation, and differentiation, thus affecting hematopoiesis and contributing to the overall disease pathology.

References

1. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nature reviews Disease primers. 2018;4(1):1-22.
2. Tebbi CK. Sickle cell disease, a review. Hemato. 2022;3(2):341-366.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
7. Piccin A, Murphy C, Eakins E, Rondinelli MB, Daves M, Vecchiato C, Wolf D, Mc Mahon C, Smith OP. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. European journal of haematology. 2019;102(4):319-330.
8. Nader E, Romana M, Connes P. The red blood cell—inflammation vicious circle in sickle cell disease. Frontiers in immunology. 2020; 11:454.
9. Henry ER, Cellmer T, Dunkelberger EB, Metaferia B, Hofrichter J, Li Q, Ostrowski D, Ghirlando R, Louis JM, Moutereau S, Galactéros F. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Proceedings of the National Academy of Sciences. 2020;117(26):15018-15027.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
11. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
12. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.

13. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
14. Warren LA, Rossi DJ. Stem cells and aging in the hematopoietic system. Mechanisms of ageing and development. 2009;130(1-2):46-53.
15. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immuno-modulation of hematopoietic stem and progenitor cells in inflammation. Frontiers in immunology. 2020; 11:585367.
16. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
17. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
18. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
19. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
20. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
21. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
22. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
23. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
24. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
25. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
26. Renó CO, Barbosa AR, de Carvalho SS, Pinheiro MB, Rios DR, Cortes VF, Barbosa LA, Santos HL. Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea. Annals of Hematology. 2020; 99:937-945.
27. Tousoulis D, Briasoulis A, Vogiatzi G, Valatsou A, Kourkouti P, Pantopoulou A, Papageorgiou N, Perrea D, Stefanadis C. Infusion of lin−/sca-1+ and endothelial progenitor cells improves proinflammatory and oxidative stress markers in atherosclerotic mice. International journal of cardiology. 2013;167(5):1900-1905.

28. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
29. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
30. Akinsheye I, Klings ES. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. Journal of cellular physiology. 2010;224(3):620-625.
31. Harada K, Yahata T, Onizuka M, Ishii T, Aziz Ibrahim A, Kikkawa E, Gondo Y, Ando K. Mitochondrial electron transport chain complex II dysfunction causes premature aging of hematopoietic stem cells. Stem Cells. 2023;41(1):39-49.
32. Bhatt S, Argueta DA, Gupta K, Kundu S. Red blood cells as therapeutic target to treat sickle cell disease. Antioxidants & Redox Signaling. 2024;40(16-18):1025-1049.
33. Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxidants & redox signaling. 2008;10(11):1923-1940.
34. Domingues MJ, Cao H, Heazlewood SY, Cao B, Nilsson SK. Niche extracellular matrix components and their influence on HSC. Journal of cellular biochemistry. 2017;118(8):1984-1993.
35. Engwa GA, Okolie A, Chidili JP, Okore PA, Onu PC, Ugwu MO, Oko DE, Ferdinand PU. Relationship of oxidative stress and antioxidant response with vaso-occlusive crisis in sickle cell anaemia. African Health Sciences. 2021;21(1):150-158.
36. Castilhos LG, de Oliveira JS, Adefegha SA, Magni LP, Doleski PH, Abdalla FH, de Andrade CM, Leal DB. Increased oxidative stress alters nucleosides metabolite levels in sickle cell anemia. Redox Report. 2017;22(6):451-459.
37. Pavan AR, Terroni B, Dos Santos JL. Endothelial dysfunction in Sickle Cell Disease: Strategies for the treatment. Nitric Oxide. 2024.
38. Javazon EH, Radhi M, Gangadharan B, Perry J, Archer DR. Hematopoietic stem cell function in a murine model of sickle cell disease. Anemia. 2012;2012(1):387385.
39. Porto ML, Rodrigues BP, Menezes TN, Ceschim SL, Casarini DE, Gava AL, Pereira TM, Vasquez EC, Campagnaro BP, Meyrelles SS. Reactive oxygen species contribute to dysfunction of bone marrow hematopoietic stem cells in aged C57BL/6 J mice. Journal of Biomedical Science. 2015; 22:1-3.
40. Sesti-Costa R, Costa FF, Conran N. Role of macrophages in sickle cell disease erythrophagocytosis and erythropoiesis. International Journal of Molecular Sciences. 2023;24(7):6333.
41. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and

erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.

42. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
43. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
44. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
45. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
46. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):58-66.
47. Jaja SI, Ogungbemi SO, Kehinde MO, Anigbogu CN. Supplementation with l-arginine stabilizes plasma arginine and nitric oxide metabolites, suppresses elevated liver enzymes and peroxidation in sickle cell anaemia. Pathophysiology. 2016;23(2):81-85.
48. Wagner JL, O'Connor DM, Donsante A, Boulis NM. Gene, stem cell, and alternative therapies for SCA 1. Frontiers in Molecular Neuroscience. 2016; 9:67.
49. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nature reviews Drug discovery. 2015;14(9):623-64